• Condensate Coronas and Nanoparticle Cargo Transfer

  2026-10-21

  A 2026 Nature Materials study describes a rare class of nanoparticle–cell hybrids that acquire condensate-like, cell-derived coronas and transfer proteins and RNA between cells. The evidence supports a model in which intracellular recognition, rather than passive extracellular adsorption alone, generates a biologically privileged particle state. Proteomics, RNA sequencing, imaging and functional reporter assays converge on this interpretation, while the prevalence, molecular recognition rules and contribution of membrane-associated material remain unresolved.

• How to Interpret Schizandrin B Evidence

  2026-10-21

  What can a named molecular material establish about mechanism or biological activity? For Schizandrin B, the supplied record supports material identity and a framework for interpreting future evidence, but it does not document a molecular target, pathway effect, assay result, or product-specific performance.

• How to Interpret β-Muricholic Acid Evidence

  2026-10-20

  β-Muricholic acid is best interpreted by separating chemical identity from biological mechanism and measured outcome. The supplied record identifies the material but does not report a receptor interaction, model system, treatment effect, or quantitative result. Established bile-acid biology provides a useful conceptual framework, but it does not by itself validate a specific product, study outcome, or functional claim.

• Tropisetron Hydrochloride: Evidence and Scope

  2026-10-19

  The APExBIO catalog identifies Tropisetron Hydrochloride (SKU B2258; SDZ-ICS 930) as a hydrochloride salt described as a selective 5-HT3 receptor antagonist and an α7-nicotinic receptor agonist. Its reported 5-HT3 IC50 of 70.1 ± 0.9 nM is a catalog-attributed assay value, not an assay-independent measure of affinity or proof of downstream biological effects; no identity-matched research paper, model, comparator, sample size, or outcome dataset is available in the provided evidence.

• NB-598 Hydrochloride: Evidence Boundaries

  2026-10-18

  APExBIO’s product page identifies NB-598 hydrochloride by name and SKU A3646, but the available documentation does not provide a mechanism, assay principle, research outcome, or identity-matched publication. The material therefore supports catalog-level provenance only, not claims about biological activity, selectivity, potency, or application.

• β-Hyodeoxycholic Acid: Evidence and Scope

  2026-10-17

  The APExBIO listing identifies β-hyodeoxycholic acid in a hydrate form under SKU C8610, but the supplied product information does not document a mechanism, measurement principle, study result, or independent identity confirmation. Accordingly, the material can be discussed as a named product entity and a potential subject of research inquiry, but not as a demonstrated biological reagent or validated mechanistic probe.

• PDGF-BB: Identity, Mechanism and Evidence Scope

  2026-10-16

  A source-grounded overview of APExBIO’s murine recombinant PDGF-BB describes its molecular identity, receptor context, reported mitogen assay, product characterization and key evidence boundaries. The supplier-reported BALB/c 3T3 response supports assay-specific biological activity, but it does not establish independent replication, broad cell-type performance, disease relevance or therapeutic utility.

• EZ Cap Gaussia Luciferase mRNA: Evidence Scope

  2026-10-16

  The APExBIO product page identifies SKU R1129 as EZ Cap™ Gaussia Luciferase mRNA (m1Ψ), but no identity-matched research study or product-specific outcome data are available here. The documented identity supports a conceptual reporter-measurement framework, not claims about performance, delivery, translation, stability, immunogenicity, or comparative efficacy.

• When Context Changes a Molecular Result

  2026-10-15

  A reported molecular result acquires meaning from its biological model, genetic background, phosphorylation state, affinity tag, assay format and downstream readout. The 2026 birch study supports a phosphorylation-sensitive BpSRK1–BpERF3–BpHDA6 pathway within the tested systems, but its findings do not establish supplier-specific reagent performance, universal cross-species behavior or a complete structural mechanism.

• Hematoxylin and Eosin Staining: Evidence and Scope

  2026-10-15

  The APExBIO Hematoxylin and Eosin Staining Kit (SKU K1142) is described as a ready-to-use two-dye system for qualitative visualization of nuclei, cytoplasm, extracellular matrix, and overall tissue morphology. Its documented mechanism supports interpretation of blue-to-purple nuclear contrast and pink-to-red protein-rich structures, but the available product information does not establish quantitative performance, diagnostic validity, or outcomes from an identity-matched research study.

• FH1: What the Product Record Supports

  2026-10-14

  The APExBIO product record identifies FH1 (B3700) as a small molecule associated with improved maturation-associated features in iPS cell-derived hepatocyte-like cells. It reports higher albumin secretion, increased CYP3A4 levels, reduced AFP secretion, and more pronounced hepatocyte-like morphology, but provides no identity-matched research paper, molecular target, sample size, uncertainty estimates, or detailed comparator information. These observations support a product-level hypothesis about cultured hepatocyte function enhancement, not an independently established mechanism or clinical application.

• Drying mRNA-LNPs: What the 2026 Review Shows

  2026-10-14

  Zhen and colleagues’ 2026 review examines whether drying technologies can improve the storage stability of mRNA and other nucleic-acid lipid nanoparticles. It offers a conceptual comparison of freeze-drying and emerging approaches, while emphasizing that cargo structure, formulation, reconstitution behavior, and biological potency determine whether a dried product remains fit for purpose.

• Thapsigargin, Calcium Signaling, and Necroptosis

  2026-10-13

  A source-grounded overview of how SERCA-mediated calcium homeostasis relates to rotavirus-associated necroptosis, and why thapsigargin should be treated as a broad pharmacological perturbant rather than a direct surrogate for viral NSP4.

• Angiotensin Peptides and Spike–Receptor Binding

  2026-10-13

  A 2025 biochemical study reports that several naturally occurring angiotensin peptides increased SARS-CoV-2 spike-protein binding to host receptors, with effects that depended on peptide length, sequence position, and tyrosine modification. The findings are mechanistic and hypothesis-generating, not evidence that these peptides increase infection or worsen COVID-19 in humans.

• VEGFR-3 Inhibition in NASH Fibrosis: What We Know

  2026-10-12

  A 2026 Phytomedicine study links hepatocyte-derived VEGFC to macrophage recruitment and phenotype in a mouse model of metabolic liver fibrosis. Pharmacologic inhibition with SAR131675, naringin treatment, and hepatocyte-specific Vegfc deletion produced convergent protective findings, but the evidence remains preclinical and does not establish clinical efficacy, mechanism exclusivity, or superiority of one intervention.

8507 records 1/568 page Next 12345 下5页 Last page